1. Home
  2. ITOS vs ACNB Comparison

ITOS vs ACNB Comparison

Compare ITOS & ACNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITOS
  • ACNB
  • Stock Information
  • Founded
  • ITOS 2011
  • ACNB 1857
  • Country
  • ITOS United States
  • ACNB United States
  • Employees
  • ITOS N/A
  • ACNB N/A
  • Industry
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • ACNB Major Banks
  • Sector
  • ITOS Health Care
  • ACNB Finance
  • Exchange
  • ITOS Nasdaq
  • ACNB Nasdaq
  • Market Cap
  • ITOS 450.9M
  • ACNB 450.1M
  • IPO Year
  • ITOS 2020
  • ACNB N/A
  • Fundamental
  • Price
  • ITOS N/A
  • ACNB $44.91
  • Analyst Decision
  • ITOS Hold
  • ACNB Strong Buy
  • Analyst Count
  • ITOS 6
  • ACNB 3
  • Target Price
  • ITOS $10.40
  • ACNB $50.00
  • AVG Volume (30 Days)
  • ITOS 1.6M
  • ACNB 21.1K
  • Earning Date
  • ITOS 08-06-2025
  • ACNB 10-23-2025
  • Dividend Yield
  • ITOS N/A
  • ACNB 3.03%
  • EPS Growth
  • ITOS N/A
  • ACNB N/A
  • EPS
  • ITOS N/A
  • ACNB 2.69
  • Revenue
  • ITOS N/A
  • ACNB $123,053,000.00
  • Revenue This Year
  • ITOS N/A
  • ACNB $40.40
  • Revenue Next Year
  • ITOS N/A
  • ACNB $4.84
  • P/E Ratio
  • ITOS N/A
  • ACNB $16.70
  • Revenue Growth
  • ITOS 177.89
  • ACNB 15.31
  • 52 Week Low
  • ITOS $4.80
  • ACNB $35.70
  • 52 Week High
  • ITOS $17.63
  • ACNB $50.72
  • Technical
  • Relative Strength Index (RSI)
  • ITOS 1.63
  • ACNB 52.57
  • Support Level
  • ITOS $10.10
  • ACNB $43.81
  • Resistance Level
  • ITOS $10.17
  • ACNB $46.70
  • Average True Range (ATR)
  • ITOS 0.03
  • ACNB 1.07
  • MACD
  • ITOS -1.20
  • ACNB -0.09
  • Stochastic Oscillator
  • ITOS 0.00
  • ACNB 54.03

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

About ACNB ACNB Corporation

ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.

Share on Social Networks: